NASDAQ:AIFC ALT5 Sigma Q3 2025 Earnings Report $0.66 +0.00 (+0.53%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast ALT5 Sigma EPS ResultsActual EPS$0.29Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AALT5 Sigma Revenue ResultsActual Revenue$7.58 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AALT5 Sigma Announcement DetailsQuarterQ3 2025Date1/12/2026TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile ALT5 Sigma Earnings HeadlinesA Trump crypto bet vaporized 92% of this stock—but here's why the CEO won't sellJune 12 at 3:42 AM | msn.comCompany that bet big on Trump-backed crypto says its fortunes have improvedJune 10 at 8:14 PM | msn.comDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concerns about government authority to freeze or seize private accounts. Greece raided pensions. Cyprus drained bank accounts. Poland seized retirement funds. Priority Gold has put together a free Wealth Defense Guide for Americans looking to move assets beyond potential government reach.June 12 at 1:00 AM | Priority Gold (Ad)Trump Family Scores Massive Payday as Company Falls ApartJune 10 at 8:14 PM | msn.comTrump family stiffed investors to make $500 million in crypto dealJune 9 at 7:51 PM | msn.comAIFC AI Financial CorporationMay 15, 2026 | seekingalpha.comSee More ALT5 Sigma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ALT5 Sigma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ALT5 Sigma and other key companies, straight to your email. Email Address About ALT5 SigmaALT5 Sigma (NASDAQ:AIFC) Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.View ALT5 Sigma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?Why Oracle's 10% Drop May Be Telling the Wrong StorySpotify's "North Star" Outlook Was Music to Investors EarsCracker Barrel Surges 23% as Earnings Beat Signals Turnaround ProgressChewy’s Growth Engine Is Stronger Than the Market ThinksCasey’s Is Looking Like a Hot Buy as Growth, Buybacks, and Guidance AlignThe “Duck Stock” Keeps Quietly Making Money for Shareholders Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
